Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
As per available reports about 10 Relevant Journals, 6 Conferences, 4 National Symposiums are presently dedicated exclusively to Diabetic Ketoacidosis and about 7 articles are being published on Diabetic Ketoacidosis.
Diabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes that mainly occurs in patients with Type 1 diabetes has, but it can occur in those with type 2 diabetes under certain circumstances. DKA results from a shortage of insulin, in response the body switches to burning fatty acids and producing acidic ketone bodies that cause most of the symptoms and complications. The most common early symptoms of DKA are the insidious increase in polydipsia and polyuria. The other signs and symptoms of DKA are generalized weakness, fatigability, nausea; vomiting, rapid weight loss, decreased perspiration and this may be undercurrent illness pneumonia, influenza, gastroenteritis, urinary tract infection.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and importance
Diabetic ketoacidosis (DKA) is rapidly affecting the people, yet the systematic application of current knowledge to improve patient care remains a formidable challenge. Diabetic ketoacidosis (DKA) arises because of a lack of insulin in the body. DKA is common in type 1 diabetes as this form of diabetes is associated with an absolute lack of insulin production by the islets of Langerhans. In type 2 diabetes, insulin production is present but is insufficient to meet the body's requirements as a result of end-organ insulin resistance The most common mechanism is relative insulin deficiency (insulinopaenia) and usual triggers are non-concordance or infection. Treatment is exactly the same as in type 1 diabetes with intravenous fluid resuscitation and insulin, though the duration of treatment may not be as long. These patients are able to stop insulin following resolution of ketoacidosis and can be managed on oral hypoglycaemic agents. It is important for clinicians to be aware of this condition due to the increasing burden of type 2 diabetes and to avoid unnecessary treatment with insulin in the long term.
Old Content
Diabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes that mainly occurs in patients with Type 1 diabetes has, but it can occur in those with type 2 diabetes under certain circumstances. DKA results from a shortage of insulin, in response the body switches to burning fatty acids and producing acidic ketone bodies that cause most of the symptoms and complications. The most common early symptoms of DKA are the insidious increase in polydipsia and polyuria. The other signs and symptoms of DKA are generalized weakness, fatigability, nausea; vomiting, rapid weight loss, decreased perspiration and this may be undercurrent illness pneumonia, influenza, gastroenteritis, urinary tract infection.
Diabetic ketoacidosis (DKA) is rapidly affecting the people, yet the systematic application of current knowledge to improve patient care remains a formidable challenge. National symposiums and Workshops provide a dedicated forum for the advancement, implementation and exchange of information about DKA and its allied areas. Many Organizations are getting involved in conducting symposiums and workshops to share awareness about DKA, which includes International society for pediatric and adolescent diabetes (ISPAD), National Institute for Health Research (NHS), Royal College of Pediatrics & Child Health, Diabetics Teaching Center UCSF, and Death to Diabetes.
Diabetic ketoacidosis (DKA) arises because of a lack of insulin in the body. DKA is common in type 1 diabetes as this form of diabetes is associated with an absolute lack of insulin production by the islets of Langerhans. In type 2 diabetes, insulin production is present but is insufficient to meet the body's requirements as a result of end-organ insulin resistance. Usually, these amounts of insulin are sufficient to suppress ketogenesis. If DKA occurs in someone with type 2 diabetes, their condition is called "ketosis-prone type 2 diabetes". The exact mechanism for this phenomenon is unclear, but there is evidence both of impaired insulin secretion and insulin action. Once the condition has been treated, insulin production resumes and often the patient may be able to resume diet or tablet treatment as normally recommended in type 2 diabetes. The clinical state of DKA is associated, in addition to the above, with the release of various counter regulatory hormones such as glucagon and adrenaline as well as cytokines, the latter of which leads to increased markers of inflammation, even in the absence of infection.
Market Analysis
Diabetic ketoacidosis (DKA) a hyperglycemic crisis most commonly associated with type 1 diabetes mellitus (T1DM) is often the first symptom of diabetes to appear in the undiagnosed population. Managing the condition effectively to prevent incidence is important because of the associated morbidity and resulting economic impact. Studies have shown that hospitalizations resulting from DKA amount to an annual cost of more than $2.4 billion in the United States. In the largest multinational analysis of diabetic ketoacidosis in pediatric type 1 diabetes patients, T1D Exchange researchers found consistently high rates and common risk factors for DKA across five countries, confirming that DKA a largely preventable condition remains a serious threat for type 1 diabetes patients
The analysis also highlights the considerable costs associated with treating DKA, which creates a serious financial burden for healthcare systems, patients, and families. Researchers examined data from nearly 50,000 pediatric type 1 diabetes patients ages two through 18 via three massive databases: the T1D Exchange Clinic Registry, the most comprehensive type 1 diabetes database in the U.S., comprising more than 27,000 patients from 76 pediatric and adult endocrinology centers; the Diabetes Prospective Follow-up (DPV) registry, which has more than 40,000 patients from 209 centers in Germany and Austria; and the National Pediatric Diabetes Audit (NPDA) of nearly 16,350 patients who attend pediatric diabetes units in England and Wales.
List of best International Conferences:
List of Related Societies
List of Related Companies
This page will be updated regularly.
This page was last updated on November 23, 2024
